DEXA-ARDS
2021 Respiratory
17 ICUs
277 patients
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial
Clinical Question
In patients with moderate-severe ARDS, does dexamethasone in addition to
routine care, compared with routine care alone increase ventilator free days up to day 28?
Critical Appraisal
Key findings
Primary outcome: Number of ventilator free days – significantly greater in the
dexamethasone group 12.3 (SD 9.9) vs 7.5 (SD 9.0)Difference 4.8 days (95% CI 2.57-7.03), p<0.0001
Critique
Early administration of dexamethasone could reduce duration of mechanical
ventilation and overall mortality in patients with established moderate-to-severe ARDS
- Population
- ARDS
- Population Details
- Not recorded
- Intervention Arms
-
Steroids
- Control Arms
-
Standard Care
- Primary Outcome
- Ventilator free days at day 28
- Secondary Outcomes
- Not recorded
- P Value
- 0.01
Outcome Results
Not recorded
Primary location: Spain